Abstract
Approximately 20-30% of non-small cell lung cancers (NSCLC) have mutations in the NRF2 pathway. Due to their ability to induce the expression of antioxidant genes and protect the tumor cell from cell death, these mutations have been associated with a poor prognosis and resistance to chemotherapy and immunotherapies. Ferroptosis is a recently discovered type of programmed cell death, which…